Proteocyte Announces Joseph Geraci, Ph.D. as Strategic Advisor, A.I.

Toronto, ON; June 12, 2024 – Proteocyte is pleased to announce the appointment of Joseph Geraci, Ph.D. to the new role of Strategic Advisor, A.I., effective June 3, 2024.

Dr. Geraci has a very strong academic and research background which includes a Master of Science in Mathematics from the University of Toronto, a Doctor of Philosophy (Mathematical Physics/Applied Mathematics) from the University of Toronto and the University of Southern California as well as several research initiatives, clinical publications, and three post-doctoral awards.

He is a leader of innovation with over a decade of experience and success leading artificial intelligence and machine learning development projects. This includes his current role as the Chief Scientific Officer for Nurosene Health as well as technical and creative development of machine intelligence platforms and products for the NetraMark Pharma division.

Mark Hammar, CEO of Proteocyte expressed, “We are very excited to have Joe joining us here at Proteocyte. Joe’s vast knowledge in the A.I. space is a key addition to our team as we look to bring our A.I. capabilities fully in-house allowing us to broaden the use of A.I. not only for our current assay but to develop additional capabilities.”

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.